TGF‐β signaling is an important growth regulator in advanced cancer and a novel treatment approach consists of inhibiting TGF‐β signaling in order to simultaneously inhibit tumor spread and neo‐angiogenesis and improve the patient's anti‐tumor immune response. Here, TGFB1 is linked to cancer.